Immunohistochemichal expression of biomarkers: A comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1043-1050

  Taillade, L ^a   Penault Llorca, F ^b   Boulet, T ^c   Fouret, P ^c   Michiels, S ^c   Taranchon, E ^c   Mountzios, G ^a   Validire, P ^d   Domont, J ^a   Girard, P ^d   Grunenwald, D ^e   Le Chevalier, T ^a   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c IGR   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e HÔPITAL TENON   (France)

Author keywords

Biological markers; Biopsy; Correlation; Immunohistochemistry; Non small cell lung cancer; Surgical specimen

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; KI 67 ANTIGEN; PROTEIN KINASE B; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CELL IMMORTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; SIGNAL TRANSDUCTION;

EID: 34447338821     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm072     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2): 106-130.
2. Maione P, Rossi A, Airoma G et al. The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 2004; 51(1): 29-44.
3. Schlessinger J. Ligand-induced, receptor- mediated dimerization and activation of EGF receptor Cell 2002; 110: 669-672.
4. Meert AP, Martin B, Delmotte P et al. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002; 20(4): 975-981.
5. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353(2): 133-144.
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
7. Balsara BR, Pei J, Mitsuuchi Y et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25: 2053-2059.
8. Brognand J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997.
9. David O, Jett J, LeBeau H et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival cisadvantage Clin Cancer Res 2004; 10(20): 6865-6871.
10. Cappuzzo F, Magrini E, Ceresoli GL et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96(15): 1133-1141.
11. Hoeijmakers JH. Nucleotide excision repair. II: From yeast to mammals. Trends Genet 1993; 9(6): 211-217.
12. Tomkinson AE, Bardwell AJ, Bardwell L et al. Yeast DNA repair and recombination proteins Rad1 and Rad10 constitute a single-stranded-DNA endonuclease. Nature 1993; 362: 860-862.
13. Simon GR, Sharma S, Cantor A et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127(3): 978-983.
14. Olaussen K, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355(10): 983-991.
15. Meyerson M. Role of telomerase in normal and cancer cells. J Cin Oncol 2000; 18(13): 2626-2634.
16. Nakamura TM, Morin GB, Chapman KB et al. Telomerase catalyt subunit homologs from fission yeast and human. Science 1997; 277(5328): 955-959.
17. Kim NW. Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266(5193): 2011-2015.
18. Lu C, Soria JC, Tang X et al. Prognostic factors in resected stage 1 non-small-cell lung cancer: A multivariate analysis of six molecular markers. J Clin Oncol 2004; 22(22): 4575-4583.
19. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000; 182(3): 311-322.
20. Martin B, Paesmans M, Mascaux C et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis. Br J Cancer 2004; 91(12): 2018-2025.
21. Maggiore C, Mule A, Padda G. Histological classification of lung cancer. Rays 2004; 29(4): 353-355.
22. Mountain CF. The new International Staging System for lung cancer. Surg Clin North Am 1987; 67(5): 925-935.
23. Yang Y, Chen Y, Zhang C et al. Nucleolar localization of hTERT protein is associated with telomerase function. Exp Cell Res 2002; 277: 201-209.
24. Horii N, Nishimura Y, Okuno Y et al. Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2001; 49(2): 527-532.
25. Viberti L, Papotti M, Abbona GC et al. Value of Ki-67 immunostaining in preoperative biopsies of carcinomas of the lung. Hum Pathol 1997; 28(2): 189-192.
26. Bozzetti C, Franciosi V, Crafa P et al. Biological variables in non-small cell lung cancer: Comparison between immunocytochemical determination on line needle aspirates from surgical specimens and immunohistochemical determination on tissue sections. Lung Cancer 2000; 29(1): 33-41.
27. Meert AP, Martin B, Verdebout JM et al. EGF-R expression correlation between biopsy and surgical specimens of lung carcinoma. Rev Mal Respir 2003; 20(3): 347-353.
28. Meert AP, Martin B, Verdebout JM et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 2004; 44(3): 295-301.
29. Penault-Llorca F, Cayre A, Arnould A et al. Is there an immunohistochemical technique definitively solid in EGFR assessment? Oncol Rep 2006, 16(6): 1173-1179.
30. Ferrigan L, Wallace WA. Predicting non-small cell lung cancer expression of epidermal growth factor receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples. Eur J Cancer 2004; 40(10): 1589-1592.
31. Atkins D, Reiffen KA, Tegtmeier CL et al. Immunohistochemical detection of LGI R in paraffin-embedded tumor tissue: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52(7): 893-901.
32. Van den Broek LJ, Van de Vijver MJ. Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. Appl Immunohistochem Mol Morphol 2000; 8: 316-321.
33. Baker AF, Dragovich T, Ihle NT et al. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005; 11(12): 4338-4340.
34. DiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004; 84(8): 1071-1078.
35. Fergenbaum JH, Garcia-Closas M, Hewitt SM et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 2004; 13(4): 667-672.